Literature DB >> 10417510

Expression of the neuronal isoform of nitric oxide synthase (nNOS) and its inhibitor, protein inhibitor of nNOS, in pigment cell lesions of the skin.

B Ahmed1, J J Van Den Oord.   

Abstract

Nitric oxide (NO) is involved in many physiological processes. In cancer, low levels of NO are thought to enhance tumour progression and metastasis. NO is generated from arginine by NO synthase (NOS); the Ca2+-dependent neuronal isoform or nNOS (expressed by neurones and inhibited by the protein inhibitor of nNOS, PIN), is also expressed by cultured normal melanocytes and by all malignant melanoma (MM) cell lines. We studied the expression of nNOS and PIN in paraffin sections of 177 and 58 pigment cell lesions, respectively, using immunohistochemistry; the activity of the necessary cofactor NADPH was studied in 26 frozen cases. Normal melanocytes in situ lacked nNOS and PIN expression, but were NADPH +. Almost half of common acquired benign naevi expressed nNOS; however, halo naevi and congenital naevi expressed nNOS very frequently. Dysplastic naevi and MM showed variable nNOS immunoreactivity in 72% and 83% of cases, respectively. Early (Clark I and Clark II) MM displayed nNOS staining most frequently, and all MM with an invasive radial growth phase expressed nNOS in the papillary dermis. In contrast, only 67% of metastatic MM were nNOS +. PIN was coexpressed with nNOS in 40 of 58 lesions. NADPH activity was present in all nNOS + naevi, but in two malignant cases, NADPH activity was not accompanied by nNOS expression. We conclude that nNOS expression is induced de novo in benign and malignant pigment cell lesions which have all the requirements (NADPH, PIN) necessary for the production and modulation of NO. We postulate that the frequent expression of nNOS in the junctional part of dysplastic naevi may be responsible for their particular histological features. NO generated by the neoplastic dermal cells in the invasive radial growth phase may contribute to the increased number of blood vessels in the papillary dermis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10417510     DOI: 10.1046/j.1365-2133.1999.02915.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  6 in total

Review 1.  Updates of reactive oxygen species in melanoma etiology and progression.

Authors:  Feng Liu-Smith; Ryan Dellinger; Frank L Meyskens
Journal:  Arch Biochem Biophys       Date:  2014-04-26       Impact factor: 4.013

2.  Targeting nitric oxide signaling with nNOS inhibitors as a novel strategy for the therapy and prevention of human melanoma.

Authors:  Zhen Yang; Bobbye Misner; Haitao Ji; Thomas L Poulos; Richard B Silverman; Frank L Meyskens; Sun Yang
Journal:  Antioxid Redox Signal       Date:  2013-01-18       Impact factor: 8.401

3.  NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2.

Authors:  Pengfei Xu; Shuangyan Ye; Keyi Li; Mengqiu Huang; Qianli Wang; Sisi Zeng; Xi Chen; Wenwen Gao; Jianping Chen; Qianbing Zhang; Zhuo Zhong; Ying Lin; Zhili Rong; Yang Xu; Bingtao Hao; Anghui Peng; Manzhao Ouyang; Qiuzhen Liu
Journal:  J Exp Clin Cancer Res       Date:  2019-12-05

Review 4.  Main roads to melanoma.

Authors:  Giuseppe Palmieri; Mariaelena Capone; Maria Libera Ascierto; Giusy Gentilcore; David F Stroncek; Milena Casula; Maria Cristina Sini; Marco Palla; Nicola Mozzillo; Paolo A Ascierto
Journal:  J Transl Med       Date:  2009-10-14       Impact factor: 5.531

5.  Inhibition of interferon-gamma-stimulated melanoma progression by targeting neuronal nitric oxide synthase (nNOS).

Authors:  Shirley Tong; Maris A Cinelli; Naglaa Salem El-Sayed; He Huang; Anika Patel; Richard B Silverman; Sun Yang
Journal:  Sci Rep       Date:  2022-02-01       Impact factor: 4.379

6.  Redox-Related Proteins in Melanoma Progression.

Authors:  Larissa A C Carvalho; Rodrigo G Queijo; Alexandre L B Baccaro; Ádamo D D Siena; Wilson A Silva; Tiago Rodrigues; Silvya Stuchi Maria-Engler
Journal:  Antioxidants (Basel)       Date:  2022-02-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.